<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443338</url>
  </required_header>
  <id_info>
    <org_study_id>CHINA201002016-2</org_study_id>
    <nct_id>NCT01443338</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2</brief_title>
  <official_title>A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Triptergium wilfordii, and Acitretin are
      effective and safe in the treatment of patient of moderate to severe psoriasis vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in plaque psoriasis as assessed by PASI(psoriasis area and severity index) response or PASI 75 (a patient that has an improvement from baseline PASI of at least 75%)</measure>
    <time_frame>to 8 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plaque psoriasis as assessed by PASI response or PASI 50 (a patient that has an improvement from baseline PASI of at least 50%)</measure>
    <time_frame>to 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plaque psoriasis as assessed by PASI response or PASI 90 (a patient that has an improvement from baseline PASI of at least 90%)</measure>
    <time_frame>to 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters, rates of AEs, and percentage of patients requiring interruption or discontinuation of study drug due to AEs</measure>
    <time_frame>to 8 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Triptergium Wilfordii</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a kind of traditional chinese medicine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acitretin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptergium Wilfordii</intervention_name>
    <description>Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks</description>
    <arm_group_label>Triptergium Wilfordii</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acitretin</intervention_name>
    <description>Capsule,10mg/Cap,30mg Qd,no more than 8 weeks</description>
    <arm_group_label>Acitretin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults of both sexes, between the age 18 and 75 years.

          -  Have a diagnosis of psoriasis vulgaris,PASI score of 7 or greater.

          -  Capable of giving informed consent and the consent must be obtained prior to any study
             related procedures.

        Exclusion Criteria:

          -  Currently have erythrodermic,guttate or pustular psoriasis.

          -  Have any active dermatoses which may affect disease assessment of psoriasis.

          -  Have used any investigational drug,any biologic or any systemic immunosuppressants
             within the previous 1 month..

          -  Have used topical medications/treatments that could affect psoriasis or PASI
             evaluation (eg, corticosteroids, tar, phototherapy et al.) within 2 weeks.

          -  Have any acute or chronic or recurrent infectious disease,which was difficult to
             control.

          -  Have the history of HBV or HCV infection,or HIV antibody test positive.

          -  AST, ALT or blood fat levels must be within 1.5 times the ULN range for the laboratory
             conducting the test.

          -  Are pregnant, nursing, or planning pregnancy in the coming two years(both men and
             women) while enrolled in the study.

          -  Have any severe systemic disease or have a history of malignancy.

          -  Have shown a previous hypersensitivity to Triptergium wilfordii or Acitretin.

          -  Have any other condition not suitable to join in trial,which are judged by
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lunfei Liu, Dr</last_name>
    <phone>86-571-87783743</phone>
    <email>liulunfei@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jisu Chen, Dr</last_name>
    <phone>86-571-87783743</phone>
    <email>cgmcjs@msn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lunfei Liu, Md</last_name>
      <phone>86-571-87783743</phone>
      <email>liulunfei@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jisu Chen, MD</last_name>
      <phone>86-571-87783743</phone>
      <email>cgmcjs@msn.com</email>
    </contact_backup>
    <investigator>
      <last_name>Min Zheng, PHD&amp;MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lunfei Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>JIsu Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianliang Yan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianyou Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>September 28, 2011</last_update_submitted>
  <last_update_submitted_qc>September 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</investigator_affiliation>
    <investigator_full_name>Min Zheng</investigator_full_name>
    <investigator_title>Head of dermatology</investigator_title>
  </responsible_party>
  <keyword>Triptergium wilfordii</keyword>
  <keyword>Acitretin</keyword>
  <keyword>psoriasis vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acitretin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

